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Vaccination with virosomally formulated recombinant CyRPA
elicits protective antibodies against Plasmodium falciparum
parasites in preclinical in vitro and in vivo models
Marco Tamborrini 1,2*, Julia Hauser1,2, Anja Schäfer1,2, Mario Amacker 3, Paola Favuzza 1,2, Kwak Kyungtak1,2, Sylvain Fleury3 and
Gerd Pluschke1,2
The Plasmodium falciparum (Pf) cysteine-rich protective antigen (PfCyRPA) has emerged as a promising blood-stage candidate
antigen for inclusion into a broadly cross-reactive malaria vaccine. This highly conserved protein among various geographical
strains plays a key role in the red blood cell invasion process by P. falciparum merozoites, and antibodies against PfCyRPA can
efﬁciently prevent the entry of the malaria parasites into red blood cells. The aim of the present study was to develop a human-
compatible formulation of the PfCyRPA vaccine candidate and conﬁrming its activity in preclinical studies. Recombinant PfCyRPA
expressed in HEK 293 cells was chemically coupled to phosphoethanolamine and then incorporated into the membrane of
unadjuvanted inﬂuenza virosomes approved as antigen delivery system for humans. Laboratory animals were immunised with the
virosome-based PfCyRPA vaccine to determine its immunogenic properties and in particular, its capacity to elicit parasite binding
and growth-inhibitory antibodies. The vaccine elicited in mice and rabbits high titers of PfCyRPA-speciﬁc antibodies that bound to
the blood-stage parasites. At a concentration of 10 mg/mL, puriﬁed total serum IgG from immunised rabbits inhibited parasite
growth in vitro by about 80%. Furthermore, in a P. falciparum infection mouse model, passive transfer of 10 mg of puriﬁed total IgG
from PfCyRPA vaccinated rabbits reduced the in vivo parasite load by 77%. Inﬂuenza virosomes thus represent a suitable antigen
delivery system for the induction of protective antibodies against the recombinant PfCyRPA, designating it as a highly suitable
component for inclusion into a multivalent and multi-stage virosomal malaria vaccine.
npj Vaccines             (2020) 5:9 ; https://doi.org/10.1038/s41541-020-0158-9
INTRODUCTION
Malaria is a mosquito-borne disease of the tropics caused by
Plasmodium parasites. Amongst the ﬁve species that can affect
humans, Plasmodium falciparum is the most virulent, causing most
of the malaria-related deaths globally. According to the latest
World Malaria Report,1 in 2017, there were still 219 million cases of
malaria leading to 435,000 deaths. Beside this high biomedical
burden, malaria impedes social and economic development in
endemic areas.2 A reduction in the global malaria disease burden
has been achieved during the last decade by integrated disease
control programs. This gain is at risk by the potential spread of
insecticide-resistant mosquitoes and drug-resistant parasites.1
Consequently, an effective vaccine would be a complementary
tool to reduce the burden of malaria in integrated control
programs and could support efforts towards malaria elimination.3
Currently no effective malaria vaccine is commercially available,
but numerous vaccine design strategies against malaria infection,
disease or transmission are being actively pursued, including
development of subunit vaccines and whole sporozoite vaccina-
tion approaches.4
The major symptoms and pathology of malaria are associated
with merozoites invasion and replication within red blood cells.5
Therefore, a vaccine able to elicit antibodies that effectively
prevent the invasion process after release of free merozoites into
the bloodstream may reduce parasite burden, disease symptoms
and indirectly also transmission. However, extensive allelic
polymorphism and redundancy in erythrocyte invasion pathways
are limiting strain-transcending neutralisation by traditional
merozoite candidate vaccine antigens, such as apical membrane
antigen 1 (AMA1) and merozoite surface protein 1 (MSP1).3,6
Recently, a few new functionally essential and highly conserved
merozoite proteins have emerged as more promising blood-stage
candidate vaccine targets,4 including the P. falciparum cysteine-
rich protective antigen (PfCyRPA).7
PfCyRPA is a microneme-protein that is essential for merozoite
invasion. It fulﬁls its still unknown role by forming a multi-protein
complex at the interface between the merozoite and erythrocyte
together with the reticulocyte-binding homolog 5 (PfRH5) and the
RH5-interacting protein (PfRipr).8,9 This RH5/Ripr/CyRPA complex
plays a central role in the mechanism of P. falciparum merozoite
invasion as the complex is required for the establishment of tight
junctions and the triggering of Ca2+ release.9 In contrast to the
‘classical’ blood-stage vaccine candidate antigens, PfCyRPA shows
very limited genetic diversity and immunogenicity.7 PfCyRPA-
speciﬁc monoclonal antibodies (mAbs) can inhibit parasite growth
in vitro by blocking merozoite invasion and show potent in vivo
growth-inhibitory activity in P. falciparum infected NOD-scid
IL2Rγnull (NSG) mice engrafted with human erythrocytes.7,10 Like
PfCyRPA, the two other partners of the invasion complex, PfRH5
and PfRipr, are vaccine candidates, as they elicit cross-strain
invasion-inhibitory antibodies.8,11–15 Moreover, anti-PfCyRPA anti-
bodies show: (a) Additive parasite growth-inhibitory activity, when
combined with anti-RH5 antibodies both in vitro and in vivo;16
and (b) Synergistic in vitro inhibitory activity, when combined with
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antibodies against some merozoite antigens, such as anti-MSRP5
and anti-RAMA, involved in non-overlapping steps during
erythrocyte invasion.17 These ﬁndings support the inclusion of
PfCyRPA into a multi-component subunit malaria vaccine.
Subunit vaccines based on recombinant proteins typically
require co-administration with adjuvants, which are either already
mixed with the antigens or provided into two separated vials
requiring vaccine mixing prior to administration. Also effective
particle-based antigen delivery platforms have been developed to
achieve adequate immunogenicity. Some antigen delivery sys-
tems, like virosomes, can co-deliver immunostimodulators to
enhance immunogenicity further.18 Preclinical and clinical studies
have proven the suitability of inﬂuenza derived virosomes as
antigen carrier system for malaria-derived peptidomimetics and
recombinant proteins.19 These virosomes are non-replicating
virus-like particles, prepared from the membrane of solubilised
inﬂuenza virus mixed with synthetic phospholipids and vaccine
antigens with or without adjuvants. The hemagglutinin (HA)
membrane glycoprotein of the inﬂuenza virus harbours T helper
cell epitopes that enhance the immune response particularly for
small antigens, like peptides. Virosomes loaded with different
antigens can be combined to formulate a multi-component
subunit vaccine, making them a versatile and modular antigen
delivery system with an excellent tolerance and safety proﬁle in
children, adults and elderlies, based on experience with the
market approved inﬂuenza and hepatitis A virosome-based
vaccines.20
In this study, recombinant PfCyRPA expressed in mammalian
cells was lipidated and incorporated into the membrane of
human-compatible inﬂuenza virosomes. The virosomal formula-
tion without adjuvant and with surface display of recombinant
PfCyRPA was used to immunise mice and rabbits to determine its
immunogenicity and capacity to elicit parasite binding and
inhibitory antibodies capable of blocking erythrocyte invasion
in vitro and in vivo.
RESULTS
Immunogenicity of PfCyRPA virosomes in mice
Puriﬁed recombinant PfCyRPA expressed in mammalian cells was
chemically conjugated to phosphoethanolamine and then inte-
grated into the membrane of inﬂuenza virosomes. Inbred (BALB/c)
and outbred (NMRI) mice were immunised three times with a dose
of 20 μg of PfCyRPA virosomes in intervals of three weeks after
pre-immunisation with inactivated inﬂuenza virus. Pre-immune
sera and sera collected after pre-immunisation with inactivated
inﬂuenza virus showed no reactivity against PfCyRPA in ELISA. The
vaccine elicited comparable anti-PfCyRPA IgG titers in the two
tested mouse strains. Already one immunisation elicited detect-
able titers (Fig. 1a, b), and while a second immunisation led to a
strong titer increase in all animals, a third immunisation had only a
moderate further booster effect. Analyses of the induced PfCyRPA-
speciﬁc IgG subclass proﬁles showed a predominance of the
IgG1 subclass (Fig. 1c, d). In contrast to BALB/c mice, one outbred
NMRI mouse also developed low anti-PfCyRPA IgG2a and IgG2b
antibody levels.
To assess avidity maturation of PfCyRPA-speciﬁc serum IgG
upon repeated immunisation of mice with PfCyRPA virosomes,
chaotrope-based avidity measurements were performed. While
NMRI mice had low-avidity anti-PfCyRPA IgG antibodies after the
ﬁrst immunisation, respective to BALB/c mice, a ﬁve-fold increase
of the mean avidity index was observed after the third
immunisation (Fig. 1f). In BALB/c mice, the avidity after the ﬁrst
immunisation was already markedly higher than in NMRI mice,
and consequently only a gradual increase of the mean avidity
index over the course of immunisation was observed (Fig. 1e).
Induction of P. falciparum blood stage cross-reactive IgG upon
immunisation with PfCyRPA virosomes was analysed by immuno-
blotting and immunoﬂuorescence analysis (IFA) with sera
collected after the third immunisation. All immune sera of both
mouse strains were cross-reactive with PfCyRPA expressed by
blood-stage P. falciparum schizonts, as detected in immunoblot
analyses with parasite lysate. A representative example is shown in
Fig. 2a. While immune sera from NMRI mice bound consistently
to the blood-stage parasites in IFA (Fig. 2b), immune sera from
BALB/c mice yielded weaker and inconsistent immunoﬂuores-
cence staining signals.
Immunogenicity of PfCyRPA virosomes in rabbits
Preclinical proﬁling of the virosomal formulation of the recombi-
nant PfCyRPA protein was continued by immunogenicity studies
in New Zealand rabbits. While one group of rabbits was
immunised twice with PfCyRPA virosomes (40 μg PfCyRPA per
dose) after pre-immunisation with inactivated inﬂuenza virus, a
second group received three immunisations with PfCyRPA
virosomes without prior pre-immunisation with inactivated
inﬂuenza virus. Consistent with the results obtained in mice, all
immunised rabbits developed IgG antibodies that interacted with
the recombinant PfCyRPA protein in ELISA (Fig. 3a, b). Both
immunisation strategies induced an anti-PfCyRPA IgG response
already after the ﬁrst immunisation. Booster effects after the
second immunisation were observed in both groups with limited
variation in antibody titers. No signiﬁcant increase in titers
resulted from the third immunisation in the second group of
animals (Fig. 3b). Pre-immune sera and sera collected after pre-
immunisation with inactivated inﬂuenza virus showed no cross-
reactivity toward PfCyRPA in ELISA.
Immunised rabbits already developed after the ﬁrst immunisa-
tion IgG antibodies that were reactive with PfCyRPA expressed by
P. falciparum blood-stage schizonts in immunoblot analyses.
Immunoblot competition experiments conﬁrmed the binding-
speciﬁcity, since binding of immune sera to the endogenous
protein (band of ∼36 kDa) was inhibited by the recombinant
PfCyRPA protein in a concentration dependent manner, whereas
background staining of other protein bands observed with pre-
immune sera remained unaffected. A representative example is
shown in Fig. 3c. Immunisation with PfCyRPA virosomes also
induced in all rabbits tested IgG antibodies that reacted with P.
falciparum blood-stage parasites in IFA. A representative example
is shown in Fig. 3d.
In vitro and in vivo assessment of the parasite inhibitory activity of
antibodies generated in rabbits
Total serum IgG preparations from individual rabbit serum
samples taken after the ﬁnal immunisation with PfCyRPA
virosomes were puriﬁed to assess the effect of polyclonal anti-
PfCyRPA antibodies on the parasite growth. Puriﬁed IgG prepara-
tions were assessed at concentrations of 10, 5 and 1mg/mL of
total IgG for activity in a single-cycle in vitro parasite growth
inhibition assay (GIA) (Fig. 4a). Puriﬁed IgG from all immunised
rabbits showed substantial dose-dependent parasite in vitro
growth-inhibitory activities. In contrast, puriﬁed control IgG
preparations from non-immunised rabbits showed no signiﬁcant
growth-inhibitory activities against the parasite. While ≥ 80%
inhibition was observed for three rabbits at a concentration of
10mg/mL of total IgG, antibodies from the fourth rabbit (Fig. 4a,
rabbit 2 that had received two doses of PfCyRPA virosomes)
showed lower parasite growth-inhibitory activity, correlating with
an ~6 times lower anti-PfCyRPA IgG ELISA titer (Fig. 3a).
The antibody concentrations giving 50% growth inhibition (IC50
values) were determined for IgG preparations from rabbits that
received three doses of PfCyRPA virosomes in an [3H]-hypox-
anthine incorporation assay (Fig. 4b), which is commonly used to
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measure the activity of antimalarial compounds against intra-
erythrocytic forms of P. falciparum. The IC50 against 3D7 parasites
was 0.92 and 0.96 mg/mL of total IgG, respectively (Fig. 4b).
The in vivo parasite inhibitory activity of the generated anti-
PfCyRPA antibodies was evaluated in passive immunoprotection
experiments using a humanised P. falciparum NSG mouse model.
In this model, the immunodeﬁcient NSG mice engrafted with
human erythrocytes are susceptible to infection by the human P.
falciparum parasite, allowing the protective efﬁcacy of antibodies
speciﬁc for P. falciparum blood-stage antigens to be tested.
Humanised NSG mice were infected intravenously with 3 × 107
parasitized erythrocytes obtained from in vitro cultures of strain
BALB/c mice
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Fig. 1 Immunogenicity of PfCyRPA virosomes in mice. Development of anti-PfCyRPA total IgG responses in BALB/c (a) and NMRI (b) mice
after each immunisation. Sera were taken pre-immune (pre imm), after pre-immunisation with inactivated inﬂuenza virus (post ﬂu priming)
and after the ﬁrst (1. imm), second (2. imm) and third (3. imm) immunisation with PfCyRPA virosomes. Shown are serum IgG ELISA endpoint
titers of individual animals and lines represent the mean. Two independent experiments yielded comparable results; representative data of a
single assay is shown. Determination of the IgG subclass proﬁles in BALB/c (c) and NMRI (d) mice by ELISA using plates coated with
recombinant PfCyRPA. Sera from mice collected after the third immunisation were tested individually at three serum dilutions. Optical density
(OD) values form a single experiment are shown; these are representative for the two independent assays. Avidity index for the anti-PfCyRPA
IgG responses of BALB/c (e) and NMRI (f) mice three weeks after the ﬁrst, second and third immunisation. The avidity index is the NH4SCN
concentration (M) where 50% of the bound antibodies are eluted. Shown are results from a single experiment obtained with individual sera
tested in triplicates and the median (line) for each time point.
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Pf3D70087/N9 and the parasitemia evolution was monitored daily
starting on day 3 after infection. One day before infection (day 1),
groups of mice received a single dose of 10 or 5 mg of puriﬁed
total serum IgG from individual rabbits that had received three
immunisations with PfCyRPA virosomes. Control groups received
either puriﬁed serum IgG from non-immunised rabbits or PBS
without antibodies. In the PBS control group, parasitemia
(percentage of the total number of human erythrocytes that
were parasitized) reached 10.4 ± 0.5% on day 7 (6 days post
infection when the experiment was terminated; Fig. 4c). Passive
immunisation with polyclonal anti-PfCyRPA antibodies had a
substantial, dose-dependent parasite growth-inhibitory effect. The
administration of 10 mg of puriﬁed total polyclonal immune rabbit
IgG reduced parasite growth by 77.1 ± 4.7% (Fig. 4d). Parasitaemia
in these mice increased only marginally, reaching 2.4 ± 0.5% on
day 7 after antibody injection (Fig. 4c). The 5mg dose still reduced
parasite growth on average by 65.7 ± 8.7%. Puriﬁed control rabbit
IgG from non-immune animals showed no signiﬁcant growth-
inhibitory activities.
The decline in the concentration of total rabbit IgG in the
circulation of the passively immunised mice was monitored by
ELISA analysis using the puriﬁed total IgG preparations as
references. One day after antibody administration, when mice
were infected, the total rabbit IgG concentrations were estimated
to be 1.23 ± 0.64 and 0.46 ± 0.16 mg/mL of serum, for the 10 and
5mg doses, respectively. At the end of the experiment (day 7),
rabbit IgG levels had dropped to an estimated 0.29 ± 0.08 and
0.18 ± 0.07 mg/mL, for the 10 and 5mg doses, respectively.
DISCUSSION
The objective of the present study was to develop a human-
compatible formulation of the PfCyRPA vaccine candidate antigen
and to conﬁrm its protective potential in preclinical studies.
Protein subunit vaccine approaches typically require co-
administration of strong adjuvants or effective antigen delivery
systems such as virus-like particles to overcome the poor
immunogenicity of recombinant proteins. Here we tested a
monovalent candidate malaria vaccine based on the recombinant
PfCyRPA target protein displayed on the surface of inﬂuenza
virosomes, representing virus-like particles approved for use in
humans. While in this ﬁrst study unadjuvanted PfCyRPA inﬂuenza
virosomes were tested, adjuvanted human-compatible formula-
tions are under development that may offer the advantage to
have both antigens and adjuvants bound to the same particle
with no free-form adjuvant, improving the immunogenicity and
safety proﬁle of the vaccine. The concept of using antigen-loaded
inﬂuenza virosomes for vaccination against malaria in humans has
already been clinically validated with a virosomal formulation
incorporating optimised peptidomimetics derived from the
circumsporozoite protein (CSP) and the apical membrane antigen
1 (AMA-1).19 This bivalent virosomal vaccine candidate demon-
strated excellent safety, immunogenicity and pilot efﬁcacy in a
Phase 1b trial in African children.21 Antigen delivery using
inﬂuenza virosomes enables the design of multivalent vaccines,
as different populations of antigen-loaded virosomes can be
combined. This is an important prerequisite, since it is generally
assumed that a highly effective malaria subunit vaccine has to
target antigens of several developmental stages of the parasite.
PfCyRPA virosomes were immunogenic, leading to seroconver-
sion in all immunised mice and rabbits; two immunisations were
enough to elicit maximal anti-PfCyRPA IgG ELISA titers. Results
conﬁrmed that pre-immunisation of the rabbits with inactivated
inﬂuenza virus is not a prerequisite for the induction of antibodies
against heterologous antigens on virosomes and that pre-existing
inﬂuenza immunity does not prevent antibody induction.22 IgG
avidity maturation, indicative for memory B cell formation, was
evidenced by an increase in anti-PfCyRPA antibody avidity over
the course of immunisations. Besides antibody ﬁne-speciﬁcity and
binding avidity, recently also the kinetic parameters for antibody
binding to its target emerged as a key indicator of potency for
merozoite neutralising antibodies. The ability of recombinant
human anti-PfRH5 mAbs generated after vaccination with viral
vectored PfRH5 to inhibit parasite growth in vitro correlated with
antibody association-rates. Moreover, one anti-PfRH5 mAb without
neutralising activity potentiated the activities of other inhibitory
antibodies indirectly, by slowing down the invasion time of
merozoites and thereby increasing the time window for inhibitory
antibodies to act.23
The PfCyRPA vaccine-induced parasite-binding IgG antibodies,
conﬁrming that virosomes presented the lipidated recombinant
PfCyRPA protein in its native conformation to the immune system.
After having established that vaccine-induced antibodies bound
to the endogenous PfCyRPA protein expressed in the invasive
stage of the parasite blood-stage cycle, we conducted in vitro GIAs
with blood-stage parasites cultured in human red blood cells. This
analysis compares invasion and growth of parasites in the absence
and presence of antibodies. Although validation of the antibody-
mediated GIA as a correlate of protection in humans has been
difﬁcult to establish, this assay has been commonly used to select
and prioritise blood-stage vaccine candidates for ﬁnal preclinical
and clinical development. Puriﬁed total IgG preparations of all
PfCyRPA-immunised rabbits showed substantial and dose‐depen-
dent GIA activities. At a concentration of 5 mg/mL total IgG,
50–85% growth inhibition was observed with all rabbit IgG
samples. While the small number of animals per group limits
statistical interpretation of the results, higher mean activities were
observed in rabbits that received three doses of antigen-loaded
virosomes. The mean total IgG concentration giving 50% GIA for
rabbits that received three vaccine doses was 0.94 mg/mL total
IgG. This value lies within the broad range of GIA IC50 values
(between 0.38 mg/mL17 and 5.07mg/mL24) that have been
reported for total IgG generated by immunising rabbits with
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Fig. 2 Parasite cross-reactivity of anti-PfCyRPA IgG responses in
mice. a Pre-immune and immune serum samples of individual mice
were tested by immunoblotting analysis with blood-stage parasite
lysate. Sera were diluted 1:200 and a representative example
obtained with sera from a BALB/c mouse is shown. Blots derived
from the same experiment and were processed in parallel. b
Immune sera of mice were tested for parasite binding in IFA with
in vitro cultured P. falciparum blood-stage parasites. As a represen-
tative example, results obtained with sera from a NMRI mouse are
shown. The left panel shows differential interference contrast (DIC),
the middle panel DNA staining with DAPI (blue) and the right
picture is IgG immunoﬂuorescence staining with Alexa Fluor 568
conjugated secondary antibodies (red). The parasite inhibitory anti-
PfCyRPA mAb c1216 was used as positive control in both assays.
Scale bar, 5 µm.
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adjuvanted recombinant PfCyRPA. All three studies used recom-
binant PfCyRPA proteins produced in HEK 293 cells but the
immunisation strategies were not equivalent. In the study of
Bustamante et al.,17 which reported the lowest GIA IC50 value,
rabbits were immunised four times with a total amount of
0.3–0.6 mg of puriﬁed antigen. The adjuvant used has not been
reported. In the trial published by Illingworth et al.,24 rabbits were
immunised three times and each dose consisted of 100 μg antigen
and 200 μL AddaVax™ adjuvant. The differences in the GIA results
could thus have arisen from factors such as differences in antigen
dose, adjuvant activity, immunisation protocol and GIA assay
format.
In malaria vaccine development, the preclinical evaluation of
vaccine efﬁcacy in vivo is complicated by the absence of simple
non-primate animal models for P. falciparum. The development of
an improved murine model of malaria using P. falciparum
competent strains and NSG mice engrafted with human
erythrocytes,25 which was established and is extensively used for
malaria drug development, has opened new possibilities for the
preclinical evaluation and prioritisation of candidate vaccines
against erythrocytic stages of P. falciparum. We adopted the
improved P. falciparum infection mouse model for the assessment
of the efﬁcacy of antibodies against blood-stage antigens in
passive immunoprotection experiments.7 Antibody transfer
experiments in this in vivo model demonstrated dose-
dependent and reproducible growth-inhibitory effects of mouse
mAbs speciﬁc for the blood-stage vaccine candidates PfCyRPA and
PfRH5.7,10,16 In the present study, humanised NSG mice were
passively immunised with puriﬁed total IgG from individual rabbits
that received three vaccine doses of antigen-loaded virosomes.
One day after the antibody transfer, mice were infected with P.
falciparum 3D7 parasites. Passive transfer of vaccine-induced
Group 1
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Fig. 3 Immunogenicity of virosomally formulated recombinant PfCyRPA in New Zealand rabbits. Groups of two animals were immunised
twice (a) or three times (b) with antigen-loaded virosomes with (a) or without (b) pre-immunisation with inactivated inﬂuenza virus. Shown
are serum anti-PfCyRPA IgG ELISA endpoint titers of individual animals and lines represent the mean titer. Two independent experiments
yielded comparable results; representative data of a single assay is shown. c Immunoblot analysis of rabbit serum samples with blood-stage
parasite lysate. Immune serum of a representative rabbit was pre-incubated with or without recombinant PfCyRPA protein competitor and
subsequently added to cut strips. Immune serum was used at a dilution of 1:200 and the competitor at a concentration of 5, 0.5 or 0.05 μg/mL.
Individual ﬁlter stripes of each blot derived from the same experiment and were processed in parallel. d Immune sera of rabbits were tested
for parasite binding in IFA with in vitro cultured P. falciparum blood-stage parasites. Sera were diluted 1:1000 and representative examples are
shown. The anti-PfCyRPA neutralising mAb c12 served as positive control. Scale bar, 5 µm.
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polyclonal anti-PfCyRPA antibodies did not completely prevent
establishment of infection but reduced parasite growth in a dose-
dependent manner by about 77% (10mg dose) and 66% (5mg
dose) on day 6 after infection. The concentration of total rabbit
IgG in the circulation of the passively immunised mice that
received 10mg of total IgG, was estimated to be 1.23 mg/mL one
day after administration (the day of infection) and 0.29 mg/mL at
day 7 (the day of the measured ﬁnal parasitemia). These
concentrations were from the beginning of the parasite challenge
much lower than the concentration of IgG in normal rabbit serum,
which ranges from 5 to 12mg/mL. Considering in addition the
relatively quick in vivo clearance of the rabbit antibodies, while
the parasite keeps replicating, the inhibition of parasite growth is
remarkable. The PfCyRPA-speciﬁc IgG is expected to represent
only a small fraction of the total IgG. In previous passive
immunoprotection experiments with parasite inhibitory mono-
clonal antibodies, administration of 2.5 mg inhibitory anti-PfCyRPA
or anti-PfRH5 mAbs was required to achieve a maximal
parasitemia reduction of about 90%.10,16 An even higher reduction
of parasite burden (95% inhibition) was observed in the mouse
model when 2.5 mg inhibitory anti-PfCyRPA and 2.5 mg inhibitory
anti-PfRH5 mAbs were injected in combination.16
Taken together, these results demonstrate that recombinantly
expressed PfCyRPA delivered on human-compatible inﬂuenza
virosomes was immunogenic in preclinical animal models and
induced strong growth-inhibitory antibodies against P. falciparum
blood-stage parasites that were functional both in vitro and
in vivo. Recombinant PfCyRPA thus represents a highly suitable
highly conserved antigen candidate component for inclusion into
a multivalent virosomal malaria vaccine, with excellent cross-strain
inhibitory potential.
METHODS
Recombinant protein production and candidate vaccine
formulation
Recombinant P. falciparum CyRPA, a histidine-tagged protein comprising
residues 29–362 and containing no N-glycosylation sites, was produced
and puriﬁed as described.10 Brieﬂy, synthetically manufactured DNA
sequences encoding PfCyRPA were cloned into a pcDNA3.1-based
expression vector, which allows secretion of the protein of interest into
the cell culture supernatant. Plasmids were ampliﬁed by transforming
chemically competent Escherichia coli bacteria and used for transfection of
human embryonic kidney HEK 293 cells. The histidine-tagged protein was
puriﬁed from concentrated cell culture supernatant by immobilised metal
ion afﬁnity chromatography. The puriﬁed recombinant PfCyRPA protein
was lipidated prior to incorporation into the inﬂuenza virosomes
membrane derived from the ﬂu strain A/Brisbane/59/2007 (H1N1). In
short, puriﬁed PfCyRPA in 50mM HEPES pH 7.4, 142.5mM NaCl buffer was
randomly modiﬁed on accessible lysine residues by reacting with a ﬁve-
fold molar excess of 2-Iminothiolane for 30min at 4 °C, before addition of
the maleimide-derivatized phospholipid N-MCC-DPPE (1,2-Dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[4-(p-maleinimidomethyl)cyclohexane-
carboxamide], Corden Pharma LLC, Switzerland) for 1 h at room
temperature. Unused maleimide groups were quenched by the addition
of cysteine. SDS-PAGE analysis conﬁrmed the modiﬁcation of > 95% of the
PfCyRPA molecules. Native immunoblot and ELISA analysis conﬁrmed the
reactivity of the modiﬁed protein with the parasite inhibitory anti-PfCyRPA
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Fig. 4 PfCyRPA virosomes elicited polyclonal IgG antibodies with in vitro and in vivo parasite growth-inhibitory activity. a Synchronised
P. falciparum 3D7 blood-stage parasites were cultivated in vitro for 48 h in the presence of different concentrations of puriﬁed total serum IgG
antibodies from individual rabbits that received two (orange symbols) or three (blue symbols) doses of PfCyRPA virosomes. Puriﬁed IgG
antibodies from non-immune rabbit sera were used as negative controls. Two independent experiments yielded comparable results;
representative data of a single assay performed in triplicate is shown as mean ± standard deviation. b In vitro [3H]-hypoxanthine incorporation
assay to calculate the IC50 values for total IgG from individual rabbits that received three doses of PfCyRPA virosomes. Two independent
experiments yielded comparable results; data shown as mean of duplicate wells of a single assay is representative for the two independent
assays. c Passive immunisations of P. falciparum infected NSG mice. Humanised NSG mice received either two different doses of puriﬁed total
serum IgG antibodies formulated in PBS from individual rabbits that received three doses of PfCyRPA virosomes, puriﬁed IgG antibodies from
non-immune rabbit sera, growth-inhibitory anti-PfCyRPA mAb c12 or PBS. Mice were infected with P. falciparum and parasitaemia in peripheral
blood was monitored by ﬂow cytometry. d Percent parasite growth inhibition six days after infection was calculated against the parasitemia of
PBS control mice. Shown are mean values ± standard deviation of two mice per group. The observed parasite growth-inhibitory activities of
the anti-PfCyRPA antibodies were conﬁrmed in an independent passive immunoprotection experiment.
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mAb c12 to the same extend as the unmodiﬁed PfCyRPA. The virosomal
formulations with the lipidated PfCyRPA were prepared essentially as
described.20,26 The lipidated PfCyRPA was mixed with the membrane
fraction of the inactivated inﬂuenza virus strain A/Brisbane/59/2007
(H1N1), solubilized in 100mM dodecyl octaethylene glycol ether (OEG;
Sigma, Switzerland) in 50mM HEPES pH 7.4, 142.5mM NaCl buffer, and
with synthetic 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; Merck &
Cie, Switzerland). The concentrated virosome intermediate mixture with
the integrated PfCyRPA protein was obtained after removal of OEG on
polystryrene beads (Bio-Beads; Bio-Rad, Switzerland) in a batch chromato-
graphy. After determination of the PfCyRPA antigen concentration by
ELISA and native immunoblot, the ﬁnal vaccine was prepared by dilution of
the intermediate mixture to the required ﬁnal antigen concentration in
HEPES-NaCl pH 7.4 buffer, followed by a ﬁnal ﬁltration step on a 0.22 µm
PVDF syringe ﬁlter.
Immunogenicity studies in laboratory animals
Mice experiments were carried out in accordance with the national
regulations for the protection of animal rights. The protocols were ethically
approved by the veterinary ofﬁce of the county of Basel-City, Switzerland
(Permit Numbers: 2375 and 2303). Seven-week-old speciﬁc pathogen-free
Crl:NMRI(Han) (n= 3) and BALB/cAnNCrl (n= 5) mice were purchased from
Charles River Laboratories (Germany) and used for immunisation studies.
Mice were pre-immunised subcutaneously with inactivated inﬂuenza virus
(equivalence of 1 μg of haemagglutinin from A/Brisbane/59/2007 H1N1) to
induce immune responses toward viral membrane proteins for mimicking
human pre-existing inﬂuenza immunity. Three weeks later, they were
immunised subcutaneously with PfCyRPA conjugated to virosomes (20 μg
PfCyRPA per dose) in intervals of three weeks (day 0, 21 and 42). Blood was
collected before each immunisation and two weeks after the ﬁnal
injection.
New Zealand rabbits were kept, immunised and bled at Kaneka
Eurogentec S.A. (Belgium). One group of rabbits (n= 2) was immunised
twice with PfCyRPA virosomes (40 μg PfCyRPA per dose) by the
intramuscular route after pre-immunisation with inactivated inﬂuenza
virus (equivalence of 10 μg of haemagglutinin). A second group of animals
received three immunisations in intervals of at least three weeks without
pre-immunisation with inactivated inﬂuenza virus. Blood was collected
before each immunisation and three weeks after the ﬁnal injection. Total
IgG was puriﬁed from rabbit sera using protein A columns (GE Healthcare).
ELISA
For the detection of CyRPA-speciﬁc IgG antibodies in sera, Nunc
MaxiSorpTM ﬂat-bottom 96-well ELISA plates were coated with 5 μg/mL
of puriﬁed recombinant PfCyRPA protein overnight at 4 °C. After blocking
and washing, plates were incubated with serial dilutions of mouse or rabbit
sera in phosphate buffer saline (PBS) at pH 7.4 for one hour at room
temperature. The plates were then washed and incubated with goat anti-
mouse (Sigma) or anti-rabbit IgG (Jackson ImmunoResearch) conjugated to
horseradish peroxidase (HRP) secondary antibodies for 1 h at room
temperature. Tetramethylbenzidine (TMB) was used as substrate (KPL).
The reaction was stopped after appropriate time with 0.5 M H2SO4 and the
absorbance was read at 450 nm with the Sunrise absorbance plate reader
(Tecan). Data were processed and analysed using GraphPad Prism 7.
The anti-PfCyRPA IgG subclasses were determined by ELISA with alkaline
phosphatase-conjugated goat anti-mouse IgG1, IgG2a, IgG2b and
IgG3 secondary antibodies (SouthernBiotech).
In avidity ELISA analyses,27 mouse serum samples were added to
PfCyRPA-coated ELISA plates in triplicates at constant dilutions (approx.
halfmax titer). After washing, plates were incubated for 15min with
NH4SCN diluted in 0.1 M NaH2PO4 buffer (pH 6) at the following molarities:
5 M, 4 M, 3 M, 2 M, 1 M, 0.5 M, and 0.25 M. After a wash step, the plates
were incubated with goat anti-mouse HRP secondary antibodies for
detecting antibodies that remained bound to the antigen and processed
as described above. The avidity index corresponds to the NH4SCN
concentration (M) eluting 50% of the bound antibodies.
Immunoblotting
Cultured P. falciparum 3D7-infected erythrocytes were collected at the
schizont stage and treated with 0.06% saponin on ice for 20min to release
the parasites. Washed parasites were resuspended in PBS pH 7.4 and
frozen at −80 °C. After thawing, parasite cells were lysed in RIPA buffer (1%
NP40, 0.25% DOC, 10% glycerol, 2 mM EDTA, 137mM NaCl, 20 mM Tris HCl
pH 8.0, with a cocktail of protease inhibitors) for 10min on ice. The lysates
were cleared by centrifugation at 15,000 × g for 10 min and the
supernatant kept at −80 °C until use. Parasite lysates were heated to
70 °C for 10min under non-reducing conditions in LDS sample buffer and
resolved on precast 4–12% gradient gels (NuPAGETM Novex 4–12% Bis–Tris
Gel, Invitrogen). Following gel electrophoresis, separated proteins were
transferred to nitrocellulose membranes using a dry-blotting system (iBlot,
Invitrogen). After blocking, the membranes were incubated with appro-
priate dilutions of sera or mAbs in PBS for 1 h at room temperature. In
competition experiments, primary antibodies were pre-incubated for
30min with recombinant PfCyRPA protein competitor at a concentration
of 5, 0.5 or 0.05 μg/mL. After washing, blots were incubated with secondary
HRP-conjugated antibodies and bands were visualised using ECL detection
kit (Pierce). Uncropped scans of the blots from Figs 2a and 3c are shown in
the Supplementary Figs 1 and 2.
Indirect immunoﬂuorescence assay
Thin smears of synchronised P. falciparum 3D7-infected erythrocytes were
ﬁxed in 60% methanol and 40% acetone for 2 min at −20 °C, air-dried and
blocked with 3% BSA in PBS. Cells were then incubated with appropriate
dilutions of sera or mAbs in PBS for 1 h at room temperature. After
washing, cells were incubated with secondary antibodies speciﬁc for
mouse or rabbit IgG conjugated with Alexa Fluor 568 (Invitrogen). Before
the immunoreactivity was analysed with a Leica DM-5000B ﬂuorescence
microscope using a 60x oil immersion objective lens, the slides were
washed, mounted with ProLongTM Gold antifade reagent containing DAPI
(Invitrogen) and covered with a coverslip. Images were processed using
Leica Application Suite V4 and Adobe Photoshop CC.
In vitro growth inhibition assay
In vitro growth inhibition assays with the laboratory-adapted P. falciparum
3D7 clone were performed essentially as described.28 Synchronised
trophozoites were adjusted to 0.5% parasitemia and then incubated for
48 h with various concentrations of puriﬁed rabbit IgG in PBS at 1%
haematocrit. Each culture was set up in triplicate in 96-well ﬂat-bottomed
culture plates. Final parasitemia was quantiﬁed by ﬂow cytometry after
staining of viable parasites with hydroethidine and inhibition calculated
relative to infection control wells containing PBS only. The gating strategy
used for parasitemia quantiﬁcation is shown in Supplementary Fig. 3a.
IC50 values for total IgG from PfCyRPA-immunised rabbits were
determined in vitro by measuring incorporation of the nucleic acid
precursor [3H]-hypoxanthine.29 Infected red blood cells were exposed to
increasing concentrations of puriﬁed total rabbit IgG in culture plates. After
48 h of incubation, 0.5 μCi [3H]-hypoxanthine was added to each well.
Cultures were incubated for further 24 h before they were harvested onto
glass-ﬁbre ﬁlters and washed with distilled water. The radioactivity was
counted using a Betaplate liquid scintillation counter. The results were
recorded as counts per minute per well at each IgG concentration and
expressed as percentage of the untreated controls. For each individual
rabbit a four-parameter sigmoidal dose-response curve was ﬁtted to the
relationship between log10(antibody concentration) and % inhibition, and
then used to interpolate IC50 values. Data were processed and analysed
using GraphPad Prism 7.
Passive immunisations of P. falciparum infected NSG mice
The in vivo parasite inhibitory activity of the generated polyclonal anti-
PfCyRPA antibodies was tested in the P. falciparum mouse infection model
essentially as described.7,25 Six to eight week old female NSG mice (The
Jackson Laboratory) were injected almost daily with 0.75mL of human
erythrocytes suspended in RPMI 1640 solution and decomplemented
human serum at 50% haematocrit. Eleven days after the start of blood
injections, groups of humanised mice (n= 2) received a single dose of 10
or 5mg of puriﬁed total serum IgG antibodies by intraperitoneal injection.
The following day, mice were infected intravenously with 3 × 107 parasitized
erythrocytes obtained from in vitro cultures (strain Pf3D70087/N9). The degrees
of engraftment and parasitemia in peripheral blood were measured by
ﬂow cytometry using SYTO-16 green ﬂuorescent nucleic acid stain
(Invitrogen) and an allophycocyanin-labelled rat anti-mouse erythrocyte
TER-119 monoclonal antibody (BD Biosciences). The gating strategy used
for parasitemia quantiﬁcation is shown in Supplementary Fig. 3b.
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Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
The datasets generated during and/or analysed during the current study are available
from the corresponding author on reasonable request.
Received: 3 October 2019; Accepted: 13 January 2020;
REFERENCES
1. World Health Organization. World malaria report 2018. (World Health Organiza-
tion, Geneva, 2018).
2. Sachs, J. & Malaney, P. The economic and social burden of malaria. Nature 415,
680–685 (2002).
3. Crompton, P. D., Pierce, S. K. & Miller, L. H. Advances and challenges in malaria
vaccine development. J. Clin. Invest. 120, 4168–4178 (2010).
4. Halbroth, B. R. & Draper, S. J. Recent developments in malaria vaccinology. Adv.
Parasitol. 88, 1–49 (2015).
5. Miller, L. H., Baruch, D. I., Marsh, K. & Doumbo, O. K. The pathogenic basis of
malaria. Nature 415, 673–679 (2002).
6. Wright, G. J. & Rayner, J. C. Plasmodium falciparum erythrocyte invasion: com-
bining function with immune evasion. PLoS Pathog. 10, e1003943 (2014).
7. Dreyer, A. M. et al. Passive immunoprotection of plasmodium falciparum-infected
mice designates the CyRPA as candidate malaria vaccine antigen. J. Immunol.
188, 6225–6237 (2012).
8. Reddy, K. S. et al. Multiprotein complex between the GPI-anchored CyRPA with
PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc.
Natl Acad. Sci. USA 112, 1179–1184 (2015).
9. Volz, J. C. et al. Essential role of the PfRh5/PfRipr/CyRPA complex during plas-
modium falciparum invasion of erythrocytes. Cell Host Microbe 20, 60–71 (2016).
10. Favuzza, P. et al. Generation of Plasmodium falciparum parasite-inhibitory anti-
bodies by immunization with recombinantly-expressed CyRPA. Malar. J. 15, 161
(2016).
11. Bustamante, L. Y. et al. A full-length recombinant Plasmodium falciparum PfRH5
protein induces inhibitory antibodies that are effective across common PfRH5
genetic variants. Vaccine 31, 373–379 (2013).
12. Chen, L. et al. An EGF-like protein forms a complex with PfRh5 and is required for
invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog. 7,
e1002199 (2011).
13. Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to
vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, 601 (2011).
14. Douglas, A. D. et al. Neutralization of Plasmodium falciparum merozoites by
antibodies against PfRH5. J. Immunol. 192, 245–258 (2014).
15. Douglas, A. D. et al. A PfRH5-based vaccine is efﬁcacious against heterologous
strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host
Microbe 17, 130–139 (2015).
16. Favuzza, P. et al. Structure of the malaria vaccine candidate antigen CyRPA and its
complex with a parasite invasion inhibitory antibody. Elife 6, e20383 (2017).
17. Bustamante, L. Y. et al. Synergistic malaria vaccine combinations identiﬁed by
systematic antigen screening. Proc. Natl Acad. Sci. USA 114, 12045–12050 (2017).
18. Wu, Y., Narum, D. L., Fleury, S., Jennings, G. & Yadava, A. Particle-based platforms
for malaria vaccines. Vaccine 33, 7518–7524 (2015).
19. Pluschke, G. & Tamborrini, M. Development of a virosomal malaria vaccine can-
didate: from synthetic peptide design to clinical concept validation. Future Virol.
7, 779–790 (2012).
20. Moser, C., Müller, M., Kaeser, M. D., Weydemann, U. & Amacker, M. Inﬂuenza
virosomes as vaccine adjuvant and carrier system. Expert Rev. Vaccines 7, 779–791
(2013).
21. Cech, P. G. et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP
derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune
adults & children. PLoS ONE 6, e22273 (2011).
22. Tamborrini, M. et al. Design and pre-clinical proﬁling of a Plasmodium falciparum
MSP-3 derived component for a multi-valent virosomal malaria vaccine. Malar. J.
8, 314 (2009).
23. Alanine, D. G. W. et al. Human antibodies that slow erythrocyte invasion
potentiate malaria-neutralizing antibodies. Cell 178, 216–228 (2019).
24. Illingworth, J. J. et al. Functional comparison of blood-stage plasmodium
falciparum malaria vaccine candidate antigens. Front Immunol. 10, 1254
(2019).
25. Jiménez-Díaz, M. B. et al. Improved murine model of malaria using Plasmodium
falciparum competent strains and non-myelodepleted NOD-scid IL2Rγnull mice
engrafted with human erythrocytes. Antimicrob. Agents Chemother. 53,
4533–4536 (2009).
26. Blom, R. A. et al. Triple co-culture model of the human respiratory tract to study
immune-modulatory effects of liposomes and virosomes. PLoS ONE 11, e0163539
(2016).
27. Ferreira, M. U. & Katzin, A. M. The assessment of antibody afﬁnity distribution by
thiocyanate elution: a simple dose-response approach. J. Immunol. Methods 187,
297–305 (1995).
28. Mueller, M. S. et al. Induction of parasite growth-inhibitory antibodies by a vir-
osomal formulation of a peptidomimetic of loop I from domain III of Plasmodium
falciparum apical membrane antigen 1. Infect. Immun. 71, 4749–4758 (2003).
29. Ganapaty, S., Steve Thomas, P., Karagianis, G., Waterman, P. G. & Brun, R. Anti-
protozoal and cytotoxic naphthalene derivatives from Diospyros assimilis. Phy-
tochemistry 67, 1950–1956 (2006).
ACKNOWLEDGEMENTS
Work at Swiss TPH has been co-funded by the Commission for Technology and
Innovation, (grant 17635.1 PFLS-LS) and by Fondation Botnar (grant 6349). Mymetics
SA provided the virosome formulations for the studies.
AUTHOR CONTRIBUTIONS
Conceived the experiments and analysed the data: M.T., J.H., A.S., M.A., P.F., K.K., S.F.
and G.P. Performed the experiments: M.T., J.H., A.S., M.A. P.F. and K.K. Wrote the
paper: M.T., SF and G.P. All authors read and approved the ﬁnal paper version.
COMPETING INTERESTS
M.A. and S.F. are employees of Mymetics SA. The rest of the authors declare that
there are no competing interests.
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41541-020-0158-9.
Correspondence and requests for materials should be addressed to M.T.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2020
M. Tamborrini et al.
8
npj Vaccines (2020)     9 Published in partnership with the Sealy Center for Vaccine Development
